Re:NewCell Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Magnus Håkansson

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% Hiding

Nov 09

CEO

Magnus Håkansson (60 yo)

less than a year

Tenure

Mr. Magnus Hakansson serves as the Chairman of Departments & Stores at RNB Retail and Brands AB (publ). He serves as Acting Chief executive Officer at Re:NewCell AB (publ) since October 16, 2023. He served...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Magnus Håkansson	Acting Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Peter Schulz	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Magnus Lundmark	Chief Operation Officer	1.1yrs	geen gegevens	geen gegevens
Martin Stenfors	Head of Strategy & Sustainability	1.1yrs	geen gegevens	0.16% SEK 345.6k
Tricia Carey	Chief Commercial Officer	1.3yrs	geen gegevens	geen gegevens

1.1yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RENEW wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Berg	Independent Chairman	1.8yrs	SEK 213.00k	0.97% SEK 2.1m
Anna Attemark	Independent Director	2.8yrs	geen gegevens	geen gegevens
Mia Hemmingson	Independent Director	no data	SEK 250.00k	geen gegevens
Henrik Ager	Independent Director	2.8yrs	geen gegevens	geen gegevens
Helene Willberg	Independent Director	2.8yrs	SEK 265.00k	geen gegevens

2.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RENEW wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Re:NewCell Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024

Re:NewCell AB (publ) Announces CEO Changes

Re:NewCell AB (publ) Announces CEO Changes

Re:NewCell AB (publ) Announces CEO Changes

CEO & MD recently sold kr3.5m worth of stock

CEO & MD exercised options to buy kr35m worth of stock.

Recent updates

Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).

Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on Sales

Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on Sales

Re:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Profitability

Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target decreased by 51% to kr40.00

Consensus revenue estimates decrease by 16%, EPS upgraded

Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% Hiding

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024

Re:NewCell AB (publ) Announces CEO Changes

Re:NewCell AB (publ) Announces CEO Changes

Re:NewCell AB (publ) Announces CEO Changes

New minor risk - Market cap size

Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023

CEO & MD recently sold kr3.5m worth of stock

New minor risk - Share price stability

CEO & MD exercised options to buy kr35m worth of stock.

Second quarter 2023 earnings: EPS misses analyst expectations

Re:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024

Forecast breakeven date pushed back to 2025

Consensus EPS estimates fall by 11%

CEO & MD recently sold kr16m worth of stock

Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFO

CEO & MD exercised options to buy kr17m worth of stock.

Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023

Consensus revenue estimates fall by 20%

Consensus revenue estimates increase by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Price target decreased by 7.6% to kr204

Consensus EPS estimates fall by 11%

Price target decreased by 9.1% to kr204

Consensus revenue estimates fall by 16%

Re:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023

Forecast to breakeven in 2024

Forecast breakeven date pushed back to 2024

High number of new and inexperienced directors

Re:Newcell AB (Publ) Appoints Tricia Carey as Chief Commercial Officer

Forecast breakeven date pushed back to 2024

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Re:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Re:NewCell AB Appoints Toby Lawton as New Chief Financial Officer, Effective October 1, 2022

High number of new and inexperienced directors

Chief Financial Officer recently bought kr116k worth of stock

Re:Newcell AB (Publ) Announces Executive Changes

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023

Price target increased to kr370

High number of new and inexperienced directors

Price target increased to kr370

Forecast breakeven date moved forward to 2023

Chief Growth Officer recently sold kr65k worth of stock

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023

Re:NewCell AB (publ) Provides Production Guidance for the Year 2022

Re:NewCell AB (publ), Annual General Meeting, May 17, 2022

Chief Growth Officer exercised options to buy kr1.1m worth of stock.

Forecast to breakeven in 2024

Consensus revenue estimates increase by 67%

Chief Financial Officer recently bought kr80k worth of stock